Drysdale M - Search Results

1

Characteristics and outcomes of COVID-19 patients presumed to be treated with sotrovimab in NHS hospitals in England.

Patel V, Levick B, Boult S, Gibbons DC, Drysdale M, Lloyd EJ, Singh M, Birch HJ. Patel V, et al. Among authors: drysdale m. BMC Infect Dis. 2024 Apr 22;24(1):428. doi: 10.1186/s12879-024-09311-2. BMC Infect Dis. 2024. PMID: 38649824 Free PMC article.

2

Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19 During SARS-CoV-2 Delta and Omicron Waves in the USA.

Cheng MM, Reyes C, Satram S, Birch H, Gibbons DC, Drysdale M, Bell CF, Suyundikov A, Ding X, Maher MC, Yeh W, Telenti A, Corey L. Cheng MM, et al. Among authors: drysdale m. Infect Dis Ther. 2023 Feb;12(2):607-621. doi: 10.1007/s40121-022-00755-0. Epub 2023 Jan 11. Infect Dis Ther. 2023. PMID: 36629998 Free PMC article.

3

Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 subvariant predominance: a systematic literature review.

Drysdale M, Gibbons DC, Singh M, Rolland C, Lavoie L, Skingsley A, Lloyd EJ. Drysdale M, et al. Infection. 2024 Feb;52(1):1-17. doi: 10.1007/s15010-023-02098-5. Epub 2023 Sep 30. Infection. 2024. PMID: 37776474 Free PMC article. Review.

4

Effectiveness of Sotrovimab in Preventing COVID-19-Related Hospitalizations or Deaths Among US Veterans During Omicron BA.1.

Young-Xu Y, Korves C, Zwain G, Satram S, Drysdale M, Reyes C, Cheng MM, Bonomo RA, Epstein L, Marconi VC, Ginde AA. Young-Xu Y, et al. Among authors: drysdale m. Open Forum Infect Dis. 2023 Dec 2;10(12):ofad605. doi: 10.1093/ofid/ofad605. eCollection 2023 Dec. Open Forum Infect Dis. 2023. PMID: 38152625 Free PMC article.

5

Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19: Evidence from the US National COVID Cohort Collaborative (N3C).

Bell CF, Bobbili P, Desai R, Gibbons DC, Drysdale M, DerSarkissian M, Patel V, Birch HJ, Lloyd EJ, Zhang A, Duh MS; N3C consortium. Bell CF, et al. Among authors: drysdale m. Clin Drug Investig. 2024 Mar;44(3):183-198. doi: 10.1007/s40261-024-01344-4. Epub 2024 Feb 20. Clin Drug Investig. 2024. PMID: 38379107 Free PMC article.

6

Comparative effectiveness of sotrovimab versus no treatment in non-hospitalised high-risk COVID-19 patients in north west London: a retrospective cohort study.

Drysdale M, Galimov ER, Yarwood MJ, Patel V, Levick B, Gibbons DC, Watkins JD, Young S, Pierce BF, Lloyd EJ, Kerr W, Birch HJ, Kamalati T, Brett SJ. Drysdale M, et al. BMJ Open Respir Res. 2024 Apr 4;11(1):e002238. doi: 10.1136/bmjresp-2023-002238. BMJ Open Respir Res. 2024. PMID: 38575338 Free PMC article.

7

Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 and BA.5 subvariant predominance: a systematic literature review.

Drysdale M, Berktas M, Gibbons DC, Rolland C, Lavoie L, Lloyd EJ. Drysdale M, et al. Infection. 2024 Apr 11. doi: 10.1007/s15010-024-02245-6. Online ahead of print. Infection. 2024. PMID: 38602623

8

Plasmodium vivax in Children: Hidden Burden and Conspicuous Challenges, a Narrative Review.

Drysdale M, Tan L, Martin A, Fuhrer IB, Duparc S, Sharma H. Drysdale M, et al. Infect Dis Ther. 2023 Jan;12(1):33-51. doi: 10.1007/s40121-022-00713-w. Epub 2022 Nov 15. Infect Dis Ther. 2023. PMID: 36378465 Free PMC article. Review.

9

Use of Sotrovimab in Pregnancy: Experiences from the COVID-19 International Drug Pregnancy Registry.

Wyszynski DF, Demetriou L, Renz C, Aliabadi S, Rafailovic D, Shulman LP, Drysdale M, Wurst KE. Wyszynski DF, et al. Among authors: drysdale m. Drug Saf. 2024 May 9. doi: 10.1007/s40264-024-01439-z. Online ahead of print. Drug Saf. 2024. PMID: 38727875

10

Nontuberculous mycobacterial (NTM) infections in bronchiectasis patients: A retrospective US registry cohort study.

Drysdale M, Choate R, Brunton AE, Tiberi S, Gillespie IA, Lininger N, Shrimpton SB, Metersky M, Lapinel NC, McShane PJ, Richards CJ, Swenson C, Sharma H, Mannino D, Winthrop KL; Bronchiectasis and NTM Research Registry Investigators. Drysdale M, et al. Pulm Pharmacol Ther. 2023 Dec;83:102260. doi: 10.1016/j.pupt.2023.102260. Epub 2023 Sep 21. Pulm Pharmacol Ther. 2023. PMID: 37741357

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

85 results

Search Page